For wellness brands planning to enter both the US and EU markets, understanding the differences between FDA and EFSA regulatory frameworks is not optional — it's a prerequisite to avoiding costly reformulation and legal exposure.
Structural Differences
| Dimension | FDA (United States) | EFSA (European Union) |
|---|---|---|
| Legal Framework | DSHEA 1994 | Directive 2002/46/EC + Regulation 1925/2006 |
| Pre-Market Approval | Not required (NDI notification for new ingredients) | Novel Food authorization required for "new" ingredients |
| Claims Regulation | Structure/function claims (no pre-approval) | Health claims must be EFSA-authorised (Article 13/14) |
| Ingredient Lists | No positive list; GRAS or NDI pathway | Positive lists exist for vitamins/minerals; Novel Food for others |
| GMP Requirements | 21 CFR Part 111 | Varies by member state; Directive 2002/46 sets baseline |
| Labeling | Supplement Facts panel, %DV | Nutrition declaration, NRV (Nutrient Reference Values) |
| Enforcement | FDA warning letters, DOJ action | Varies by member state; coordinated via RASFF alerts |
Claims: The Biggest Practical Difference
United States (FDA)
- Structure/function claims ("supports immune health") allowed without pre-approval
- Must include disclaimer: "This statement has not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease."
- Disease claims prohibited for supplements
European Union (EFSA)
- Authorised health claims only — EFSA maintains a register of approved wording
- Most botanical claims are still "on hold" (pending evaluation since ~2010)
- Article 13.1 claims (general function): ~260 authorised
- Article 14 claims (disease risk reduction / children): ~15 authorised
- Claim wording must match the authorised text exactly
Practical Impact
In the US, you can say: "Echinacea supports immune health" In the EU, you generally cannot make any echinacea claim — most botanical claims remain on EFSA's "on hold" list.
Ingredient Compliance
US: NDI Notification
- New Dietary Ingredient notification required if ingredient was not marketed before October 1994
- 75-day pre-market notification to FDA
- Must include safety data
EU: Novel Food Authorisation
- Significantly more burdensome than NDI
- Requires comprehensive safety dossier
- Centralised procedure evaluated by EFSA
- 12–36 months timeline
- €50,000–€300,000+ cost (preparing the dossier)
- Once authorised, ingredient is added to the Union List
Practical Recommendations for Brands
Dual-Market Strategy
- Formulate to the stricter market — If EU is in scope, design for EU compliance first. It's easier to add claims for the US than remove them for the EU.
- Separate labels — Don't try to use the same label copy in both markets. The requirements are too different.
- Calcium, magnesium, vitamin D, Omega-3 — These have clear regulatory pathways in both markets and are good "bridge products."
- Botanicals (ashwagandha, rhodiola, turmeric) — Riskier in EU. Consider focusing botanical products on US only until EFSA completes the on-hold evaluations.
Manufacturing Documentation
Maintain separate technical files for FDA and EFSA. The documentation requirements overlap but are not identical. SuppBridge can help structure your technical file to satisfy both frameworks from the start.
Forthcoming Changes
- FDA: Proposed mandatory product listing rule would require all supplements to be registered with FDA (currently in rulemaking)
- EU: Revision of the Food Supplements Directive is expected to introduce more harmonised maximum levels for vitamins and minerals
Need help navigating FDA and EFSA requirements for your product launch? Talk to our regulatory team →
Ready to turn insights into action?
Start a Conversation →